Twist Bioscience's Q4 Earnings And Q1 Guidance Surpass Expectations, Stock Jumps
Twist Bioscience's Q4 Earnings And Q1 Guidance Surpass Expectations, Stock Jumps
Total orders received for the fourth quarter of fiscal 2024 grew 24% to $88.2 million compared to $71.1 million for the same period of fiscal 2023. Gross margin improved to 45.1%, up from 36.6% a year ago.On Monday, Twist Bioscience Corporation (NASDAQ:TWST) reported a fourth-quarter loss per share of 59 cents, beating the consensus loss of 70 cents.
週一，Twist Bioscience 公司（納斯達克: TWST）報告第四季度每股虧損爲59美分，超過70美分的共識虧損。
Twist Bioscience reported fourth-quarter sales of $84.71 million, up 27% year-over-year, beating the consensus of $82.2 million and the management guidance of $82 million–$83 million.
Twist Bioscience 報告第四季度銷售額爲8471萬美元，同比增長27%，超過8220萬美元的共識和8200萬至8300萬美元的管理指導。
The company shipped products to approximately 3,562 customers in fiscal 2024, compared to approximately 3,450 in 2023. Twist shipped approximately 772,000 genes in 2024 compared to approximately 634,000 genes a year ago.
該公司在2024財年向約3562名客戶發貨，而在2023年約爲3450名。相比一年前，Twist 在2024年發貨了約772,000個基因，而上年約爲634,000個基因。
Total orders received for the fourth quarter of fiscal 2024 grew 24% to $88.2 million compared to $71.1 million for the same period of fiscal 2023. Gross margin improved to 45.1%, up from 36.6% a year ago.
2024財年第四季度的總訂單金額同比增長24%，達到8820萬美元，而2023財年同期爲7110萬美元。毛利率提升至45.1%，較一年前的36.6%有所提高。
"As we head into fiscal 2025, we're building on this momentum as we continue our final push toward achieving adjusted EBITDA breakeven while investing in research and development to deliver precision, efficiency and scalability in products and services that continue to generate profitable growth," said Emily Leproust, CEO and co-founder of Twist Bioscience.
"隨着我們進入2025財年，我們將在這一動力的基礎上繼續最終推動實現調整後的EBITDA盈虧平衡，同時投資於研發，以提供在產品和服務中提供準確性、效率性和可擴展性，持續帶來有利可圖的增長，" Twist Bioscience 的CEO兼聯合創始人Emily Leproust說。
Adjusted EBITDA for the fourth quarter of fiscal 2024 was $(17.0) million compared to $(26.4) million for the same period of fiscal 2023
2024財年第四季度調整後的EBITDA爲負17.0百萬美元，而2023財年同期爲負26.4百萬美元。
Guidance: Twist Bioscience expects fiscal year 2025 sales of $367 million – $377 million, up 17% – 20% year over year, versus a consensus of $371.42 million.
指引: Twist Bioscience 預計2025財年銷售額爲36700萬美元至37700萬美元，同比增長17%至20%，相對共識的37142萬美元。
The guidance includes SynBio's revenue guidance of approximately $142 million – $146 million, up 15% – 18%. NGS revenue of $204 million – $209 million, up 20% – 24%. Biopharma revenue is expected to be approximately $21 million – $22 million, up 5% – 8%.
該指引包括 SynBio 的營收指引約爲14200萬美元至14600萬美元，同比增長15%至18%。NGS 的營收爲20400萬美元至20900萬美元，同比增長20%至24%。生物製藥的營收預計約爲2100萬美元至2200萬美元，同比增長5%至8%。
The gross margin is projected to be approximately 48% for fiscal 2025, with quarterly sequential improvements and a 4QFY25 gross margin of 50%. Adjusted EBITDA of approximately $(60) million to $(65) million for fiscal 2025.
預計2025財年毛利率約爲48％，季度順序改善，並且2025年第4季的毛利率爲50％。預計2025財年調整後的EBITDA約爲（60）百萬至（65）百萬美元。
The company expects first-quarter 2025 sales of around $87 million compared to the consensus of $84.47 million.
公司預計2025年第一季度銷售額約爲$8700萬，與$8447萬的共識相比。
SynBio's revenue guidance of approximately $34 million, up 26% year over year. NGS revenue of $48 million, up 22%. Biopharma revenue is expected to be approximately $5 million. Adjusted EBITDA of approximately $(20) million with sequential improvements throughout 2025.
SynBio的營業收入指引約爲$3400萬，同比增長26％。NGS營業收入爲$4800萬，增長22％。生物製藥營業收入預計約爲$500萬。預計2025年調整後的EBITDA約爲（20）百萬美元，財年內持續改善。
Price Action: TWST stock is up 12.7% at $41.59 at last check Monday.
股價走勢：TWSt股票在上週一最後一次查看時上漲12.7％至41.59美元。
Illustration of Phrama lab worker created with MidJourney
使用MidJourney創建的製藥實驗室工作者插圖
- Enphase Energy Powers Up with US-Made IQ Batteries: Unlocking Bonus Tax Credits
- enphase energy攜美國製造的IQ電池起步：解鎖額外稅收抵免
譯文內容由第三人軟體翻譯。
